Breaking Down Revenue Trends: Teva Pharmaceutical Industries Limited vs Cytokinetics, Incorporated

Teva vs. Cytokinetics: A Decade of Revenue Dynamics

__timestampCytokinetics, IncorporatedTeva Pharmaceutical Industries Limited
Wednesday, January 1, 20144694000020272000000
Thursday, January 1, 20152865800019652000000
Friday, January 1, 201610640700021903000000
Sunday, January 1, 20171336800022385000000
Monday, January 1, 20183150100018854000000
Tuesday, January 1, 20192686800016887000000
Wednesday, January 1, 20205582800016658000000
Friday, January 1, 20217042800015878000000
Saturday, January 1, 20229458800014925000000
Sunday, January 1, 2023753000015846000000
Monday, January 1, 202416544000000
Loading chart...

Unleashing the power of data

A Tale of Two Pharmaceutical Giants: Teva vs. Cytokinetics

In the ever-evolving pharmaceutical landscape, Teva Pharmaceutical Industries Limited and Cytokinetics, Incorporated have showcased contrasting revenue trajectories over the past decade. From 2014 to 2023, Teva's revenue, despite a 22% decline from its peak in 2017, remains robust, averaging around $18 billion annually. This reflects its established market presence and diverse product portfolio. In contrast, Cytokinetics, a smaller player, has experienced a more volatile revenue pattern, with a notable surge in 2016, reaching over double its 2014 figures. However, by 2023, its revenue had plummeted by approximately 86% from its 2016 high. This stark difference highlights the challenges and opportunities faced by emerging biotech firms in scaling operations and sustaining growth. As the industry continues to innovate, these trends underscore the dynamic nature of pharmaceutical revenues and the strategic maneuvers companies must undertake to thrive.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025